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Alzheimer’s disease has long been known to involve cholinergic deficits, but the linkage between cholinergic
gene expression and the Alzheimer’s disease amyloid pathology has remained incompletely understood.
One known link involves synaptic acetylcholinesterase (AChE-S), shown to accelerate amyloid fibrils formation.
Here, we report that the ‘Readthrough’AChE-R splice variant, which differs from AChE-S in its 26C-terminal
residues, inversely exerts neuroprotective effects from amyloid b (Ab) induced toxicity. In vitro, highly purified
AChE-R dose-dependently suppressed the formation of insoluble Ab oligomers and fibrils and abolished Ab
toxicity to cultured cells, competing with the prevalent AChE-S protein which facilitates these processes.
In vivo, double transgenic APPsw/AChE-R mice showed lower plaque burden, fewer reactive astrocytes and less
dendritic damage than single APPsw mice, inverse to reported acceleration of these features in double APPsw/
AChE-S mice. In hippocampi from Alzheimer’s disease patients (n=10), dentate gyrus neurons showed signifi-
cantly elevated AChE-R mRNA and reduced AChE-S mRNA.However, immunoblot analyses revealed drastic
reductions in the levels of intact AChE-R protein, suggesting that its selective loss in the Alzheimer’s disease
brain exacerbates the Ab-induced damages and revealing a previously unforeseen linkage between cholinergic
and amyloidogenic events.
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Introduction
Alzheimer’s disease has been identified as a cholinergic
deficit in the early eighties (Coyle et al., 1983), which led to
the development of cholinesterase inhibitors as the leading
currently used Alzheimer’s disease drugs (Lleo et al., 2006).
The cognitive symptoms in Alzheimer’s disease involve
learning and memory deficits accompanied by neuropsy-
chiatric disturbances, considered to be partially induced by
the loss of cholinergic neurons (Cummings and Back,
1998). These neurons notably express the acetylcholine
(ACh) hydrolysing enzyme acetylcholinesterase (AChE)
(Landwehrmeyer et al., 1993). The presence of AChE in
the amyloid plaques characteristic of Alzheimer’s disease
brains (Carson et al., 1991), the non-catalytic enhancement
of amyloid-b (Ab) fibrils formation by the major ‘Synaptic’
AChE variant [AChE-S, also called AChE-T; (Massoulie,
2002)] (Inestrosa et al., 1996) and its suppression by the
highly homologous enzyme butyrylcholinesterase [BChE;
(Diamant et al., 2006)], renewed the interest in both ACh
and cholinesterases as potential modulators of the
Alzheimer’s disease neuropathology. Supporting this
notion, muscarinic agonists attenuate both Ab and tau
pathologies and delay the development of cognitive
impairments in transgenic mice (Caccamo et al., 2006).
doi:10.1093/brain/awm276 Brain (2008), 131, 109^119
 The Author (2007). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
However, that the brain’s ACh hydrolysing activity
decreases relatively late in the Alzheimer’s disease process,
raised doubts regarding the causal involvement of AChE in
Alzheimer’s disease (Davis et al., 1999). Importantly, AChE
is not one but several proteins, because alternative splicing
and alternate promoter usage generate various forms of
AChE, differing in their N- and C-termini (Meshorer and
Soreq, 2006) but all capable of hydrolysing ACh. For
comparison, splice variants of other genes often show
inverse properties [e.g. pro-apoptotic, or anti-apoptotic
features of splice variants of Bcl2 (Shin and Manley, 2004)].
This raised the possibility that distinct AChE variants exert
various effects on the Alzheimer’s disease process.
Currently available studies on the involvement of AChE in
Alzheimer’s disease largely reflect the properties and
expression patterns of the tetramer-forming AChE-S, the
prominent variant in the mammalian brain (Soreq et al., 1990;
Ben Aziz-Aloya et al., 1993). AChE-S was shown to enhance
Ab fibrils formation in vitro (Inestrosa et al., 1996), enhance
their neurotoxic effects ex vivo (Alvarez et al., 1998) and
facilitate Alzheimer’s disease plaque formation in vivo (Rees
et al., 2005). However, aging involves a gradual increase in
the blood levels of the monomeric, soluble, stress-induced
AChE-R variant (Sklan et al., 2004), which differs from
AChE-S in its 26 C-terminal amino acid residues. AChE-R
accumulates following swim stress (Kaufer et al., 1998),
head injury, immobilization stress or exposure to cholines-
terase inhibitors (Meshorer and Soreq, 2006). Since
transgenic overexpression of AChE-R attenuates aging and
stress-associated neuropathologies, unlike AChE-S which
enhances these features (Sternfeld et al., 2000), we
specifically addressed the role of AChE-R in Alzheimer’s
disease progression. AChE-R effects were examined on Ab
fibril formation in vitro, on Ab toxicity to cultured cells
ex vivo and on amyloid plaque formation and neurotoxicity
in double-transgenic mice in vivo. Finally, ACHE
gene expression and protein levels were monitored in
hippocampus samples of human Alzheimer’s disease
patients as compared with non-demented controls (NDCs).
Materials and methods
Human brain tissue
Brain tissue from Alzheimer’s disease patients (n= 10) and NDCs
(n=5) was provided by the Netherlands Brain Bank. Ethical
approval and written informed consent from the donors or the
next of kin was obtained in all cases. Neuropathological Braak
staging of neurofibrillary changes (I–VI) was performed post-
mortem (Braak and Braak, 1991). Individual case details are
described in Table 1.
Transgenic mice
AChE-R overexpressing mice (FVB/N background) (Pick et al.,
2006) were crossed with mice transgenic for human APP-695 with
the ‘Swedish’ mutation (Hsiao et al., 1996) (B6/SJL background)
to generate double-transgenic APPsw/AChE-R mice. Backcrossing
to B6/SJL wild-type generated single and double transgenic mice.
Genotyping involved tail tip PCR. Seventy-five-week-old mice
[APPsw (n= 5) and AChE-R/APPsw (n= 5)] were anaesthetized
and perfused with ice-cold phosphate-buffered saline (PBS). One
hemisphere was postfixed overnight at 4C in 4% paraformalde-
hyde, washed with PBS and paraffin embedded. The other was
dissected and stored at 80C until protein extraction. Animal
experiments were approved by the veterinary service of the
Department of Animal Health, University of Zurich.
Immuno-blots
Human samples
Immuno-blot analysis of human hippocampal homogenate
samples involved rabbit anti-human AChE-R antibodies directed
at the unique C-terminus of AChE-R (1:700) (Sternfeld et al.,
2000), anti total AChE (H134, Santa Cruz, Santa Cruz, CA, 1:700)
and anti -tubulin (Santa Cruz, 1:2000).
Mouse samples
For insoluble Ab measurements, detergent-insoluble pellets were
resolved in 70% FA and neutralized with 10M NaOH. Extracts
were separated by 8M urea gel, blotted onto PVDF membrane,
boiled for 5min in PBS and blocked in TBS containing 4%
milk for 1 h at room temperature. Membranes were incubated
overnight with the 6E10 antibody at 4C and visualized by an
anti-mouse peroxidase-conjugated antibody (Jackson, West grove,
PA) and ECL reactions. SDS–PAGE and immuno-blot of low-salt
detergent (LSD) fraction with the 6E10 antibody was used for
amyloid-precursor protein (APP) analysis.
RNA procedures
Fresh frozen human hippocampi were coronally cut. RNA was
extracted (RNeasy lipid tissue kit, Qiagen, Valencia, CA), DNase
treated and its integrity confirmed by gel electrophoresis. cDNA
synthesis (Promega, Madison, WI) involved 0.4 mg RNA samples
in 20 ml reactions. Duplicate real-time reverse transcriptase (RT)–
PCR tests involved ABI prism 7900HT, SYBR green master mix
(Applied biosystems, Foster City, CA) and ROX, a passive
reference dye for signal normalization across the plate. Primer
Table 1 Patient details
Patient (gender; age) Diagnosis (PMD)
02-005 (f;42) AD, Braak 6 (06:10)
02-079 (f;58) AD, Braak stage unavailable (04:30)
02-056 (f;85) AD, Braak 5 (03:45)
02-061 (f;76) AD, Braak 5 (10:45)
02-080 (f;86) AD, Braak 5 (04:10)
02-085 (f;79) AD, Braak 5 (04:15)
02-088 (f;78) AD, Braak 5 (04:00)
02-099 (m;69) AD, Braak 6 (05:30)
02-102 (f;88) AD, Braak 5 (03:15)
03-009 (m;65) AD, Braak 5 (07:20)
99-067 (f;59) NDC, AD, Braak 1 (06:20)
00-017 (f;72) NDC, AD, Braak 1 (06:45)
00-025 (f;41) NDC, AD, Braak 0 (13:30)
01-021 (m;82) NDC, AD, Braak 1 (07:40)
01-046 (m;88) NDC, AD, Braak 1 (07:25)
Patient numbers, gender, age, Braak stage and post-mortem delay
(PMD) in hours are shown. NDC=non-demented control.
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sequences are listed in Table 2. Reference transcript of 18S rRNA
was used. Annealing temperature was 60C for all primers. Serial
dilution of samples served to evaluate primers efficiency and the
appropriate cDNA concentration that yields linear changes.
Melting curve analysis and amplicons sequencing verified the
identity of end products. For absolute quantification, a calibration
curve was constructed using AChE-S and AChE-R specific
plasmids.
Fluorescent in situ hybridization(FISH)
De-paraffinization of hippocampal coronal 7 mm paraffin sections
involved two washes in xylene, then in 100%, 75%, 50% and 25%
ethanol in PBT (0.13M NaCl, 7mM Na2HPO47H2O, 3mM
NaH2PO4H2O, 0.1% Tween-20), and finally twice with PBT.
Quenching was applied to suppress autofluorescence (Sun et al.,
2002). Sections were then treated with10 mg/ml proteinase K
(Boehringer Mannheim, Mannheim, Germany) for 8min and
washed with PBT. Prehybridization in 50% formamide, 5
Sodium saline citrate (SSC), 50 mg/ml yeast tRNA (Boehringer
Mannheim) and 50 mg/ml heparin (Sigma, Jerusalem, Israel) in
DDW was at 60C for 30min. Pre-heated hybridization mix
(including biotin-conjugated probes, 10 mg/ml) was added (in a
humid chamber, 90min or overnight at 52C for the AChE-S and
AChE-R probes, respectively). Two high-stringency washes at 60C
in solutions 1 (50% formamide, 5 SSC pH 4.5, 0.5% sodium
dodecyl sulphate in DDW), and 2 (50% formamide, 5 SSC
pH 4.5 in DDW) were followed by two washes in TBST
(25mM Tris–HCl pH 7.5, 136mM NaCl, 2.7mM KCl, 0.05%
Tween-20) and incubation with 1% skimmed milk in TBST to
prevent non-specific streptavidin interactions. Detection involved
40min incubation with streptavidin-conjugated Cy3 (Jackson)
diluted 1:100, at room temperature. Slides were then washed
three times with TBST, once in DDW, and mounted with
ImmunoMount (Shandon, Pittsburgh, PA). All slides were
handled simultaneously to minimize inter-slides variability.
Negative control slides were incubated with a zeta-globin probe
that is not expressed in the adult brain. The 20O-methyl,
50-Biotinylated cRNA probes (Microsynth, Balgach, Switzerland)
used in this study are detailed in Table 3.
Protein fractionation and AChE activity tests
Low-salt (LS) and LSD fractions of hippocampal homogenates
were prepared as described (Gilboa-Geffen et al., 2007). AChE
catalytic activity was measured by an adaptation of a spectro-
photometric method (Ellman et al., 1961) to a micro titre
plate assay.
Immunohistochemistry
Paraffin slices handled simultaneously to minimize inter-slides
variability were deparaffinized and blocked for 1 h in Tris 10%
serum-blocking solution. Primary antibodies were diluted in
the blocking buffer and applied for 2 h, room temperature or
overnight at 4C: Anti Ab, 6E10, 1:400 (Signet, Dedham, MA);
Anti glial fibrillary acidic protein (anti GFAP, Sigma), 1:50; Anti
microtubule-associated protein 2 (MAP2), 1:100 (Lab Vision,
Fremont, CA). Corresponding biotin-conjugated secondary anti-
bodies were used. 6E10 detection was with the ABC kit (Vector,
Burlingame, CA) with 3,30-diaminobenzidine as substrate. For
anti-MAP2 and anti-GFAP, detection involved streptavidin-
conjugated Cy3 (1:100, Jackson).
Zeiss (Oberhochen, Germany) Axioplan or Bio-Rad (Hemel
Hempsted Hers, UK) MRC- 1024 confocal microscopy served
for analysis. Labelling intensity was quantified with ImagePro Plus
4.5 (Media Cybernetics, Silver Spring, MD).
Cell culture and toxicity measurements
SH-SY5Y human neuroblastoma cells were cultured in a 1:1
mixture of Eagle’s minimum essential medium and F12 medium
(Sigma), containing 10% FCS and a mixture of 1% penicillin–
streptomycin–amphotericin (Biological industries, Beit Haemek,
Israel). Cells were plated in 48 well plates at 2105 cells/well
at 37C in a humid 5% CO2 incubator. Synthetic Ab (1-40)
peptide (Sigma) was dissolved in dimethyl sulphoxide (DMSO) at
5mM. To initiate partial fibrils formation Ab was diluted to
100 mM in PBS and incubated alone or with recombinant human
AChE-R from transgenic Nicotiana benthamiana plants (Geyer
et al., 2005) at a 1:100 ratio (1mM AChE-R), for 24 h at 37C. Ab
mixtures diluted 1:10 in low-serum medium yielding final
concentrations of 10 mM Ab and 0.1mM AChE-R were applied
to the cells for 3 days. Lactate dehydrogenase (LDH) activity
(Diamant et al., 1995) in the medium and cell counts served to
asses cellular viability.
Ab fibrils formation
For in vitro fibrils formation, synthetic Ab (1-40 or 1-42) peptides
(Sigma) dissolved in DMSO at 1.6mM were sonicated (3 5 s
Table 2 FISH probes
Probe Accession no Sequence 50 ^30 Position
hAChE-S NM_000665 ccgggggacgucgggguggg
guggggaugggcagaguc
uggggcucgucu
2022^2071
hAChE-R L42812 cuagggggagaagagaggggu
uacacuggcgggcucccac
uccccuccuc
3188^3238
hZeta-globin BC027892 tgatggtcctctcagtcttggtc
agagacatggcggcagggtg
ggcagct
17^66
Table 3 Real-time RT^PCR primers
Isoform Accession
no
Forward
primer 50 ^30
Position Reverse
primer 50 ^30
Position
hAChE-S NM_000665 cttcctccccaaattgctc 1789^1807 tcctgcttgctgtagtggtc 1901^1920
hAChE-R AY750146 cttcctccccaaattgctc 7092^7110 ggggagaagagaggggttac 7177^7196
H18S rRNA M10098 cgccgctagaggtgaaattc 1049^1068 ttggcaaatgctttcgctc 1092^1110
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pulses), filtered through 0.22 mm filters and stored in aliquots
at 70C (Klug et al., 2003). The fluorescence signal of thioflavin
T (ThT) (Sigma), a benzothiazole dye the excitation spectrum of
which shifts from 340 to 450 nm when interacting with b-sheet
amyloid structures, reflected the amount of amyloid fibrils formed
(LeVine, 1993). Aliquots of 20 ml Ab were diluted from the stock
DMSO solution to a final concentration of 162mM in PBS con-
taining 0.02% Na-Azid using 96 wells plates (Nunc, Roskilde,
Denmark). Following incubation (room temperature, 20min),
80 ml of 1.25 mM ThT in 50mM glycine buffer, pH 8.5, was added
for 6 to 10 h shaking at 200 r.p.m. and 30C. Water-dissolved
recombinant AChE variants were added to yield the indicated
molar ratio. Recombinant human AChE-S was produced in and
purified from cultured HEK293 cells (Sigma). Fluorescence was
measured at 10min intervals, using a Spectro-fluorometer (Tecan,
Maennedorf, Switzerland), with 450 nm excitation and 485 nm
emission wavelengths (Diamant et al., 2006).
Cross-linking
To specifically detect the effect of AChE-R on Ab oligomeric
forms, Ab was incubated either with or without AChE-R
(as above). At different time points, aliquots were separated to
soluble and insoluble fractions by centrifugation. Photo-induced
cross-linking of unmodified proteins [PICUP, (Fancy and
Kodadek, 1999)] with ruthenium(II) Tris–bipyridyl dication
[Ru(II)bpy3
2+] was then used to identify the different oligomeric
forms of Ab present in the supernatant fraction. The insoluble
pellet was resuspended in 8M urea and diluted to 4M. SDS–
PAGE on 10–20% Tris–tricine gels of these samples was followed
by silver staining.
Statistical analyses
All pair-wise comparisons involved the non-parametric Mann–
Whitney significance test. Correlation significance was analysed
with Pearson’s and Spearman’s tests.
Results
AChE-R attenuates whereas AChE-S facili-
tates Ab fibrils formation in vitro
To examine the specific contribution of different AChE
splice variants to amyloid fibrils formation, we studied the
in vitro aggregation behaviour of Ab1-40 or Ab1-42 in
the presence of highly purified recombinant AChE-R (Geyer
et al., 2005; Evron et al., 2007) as compared with
recombinant AChE-S (Fig. 1A). Incubation of AChE-S
with Ab1-40, at the range of 1:1000–1:1600 ratio,
predictably shortened the lag period preceding fibril
formation and accelerated the rate of ThT incorporation
into Ab fibrils, supporting previous reports of a direct
involvement of AChE-S with the progression of this process
(Inestrosa et al., 1996) (Fig. 1B). In contrast, recombinant
AChE-R in 1:400–1:1600 ratios to Ab impeded Ab fibril
formation for up to 1100min (Fig. 1C). The observed
changes involved prolonged lag time and reduced rate of
fibrils formation (Fig. 1C), inversely to the facilitation effect
of AChE-S. The effects of AChE-R and AChE-S were dose
dependent and their presence in the reaction changed the
final yield of fibrils formed (Fig. 1B and C). Since the major
amyloidogenic Ab form is the 1-42 amino acids peptide, we
repeated the ThT assay with Ab1-42 and found similar
effects (Fig. 1D and E), suggesting that AChE variants will
effect the oligomerization of both Ab variants in vivo. Since
both AChE-S and AChE-R are expressed in the human
brain it was interesting to test the simultaneous effect
of both variants. At five different molar ratios between
AChE-S and AChE-R (1:1, 1:2, 2:1, 1:5 and 5:1), AChE-R
exhibited a dominant inhibitory effect over AChE-S
(Fig. 1F). Because AChE-S and AChE-R differ in their
C-terminal domain, we predicted that this region may be
at least partially responsible for the marked differences
observed. We therefore pre-incubated AChE-R with a
specific antibody against its unique C-terminus and found
that masking this region abolished AChE-R’s ability to
inhibit fibrils formation (Fig. 1G). Interestingly, while the
pre-incubated AChE-R–antibody complex did not affect
the reaction rate or the final fibrils yield, it prolonged the
lag phase, suggesting that other domains (e.g. the peripheral
active site) may also be involved (Fig. 1G).
Different oligomeric forms of Ab vary in their effects on
neuronal toxicity and learning and memory (Ross and
Poirier, 2004; Lesne et al., 2006). Therefore, it was
important to examine the specific stage of fibrils formation
with which AChE-R interferes. To this end, we incubated
Ab1-40 with or without recombinant AChE-R, separated
the soluble from insoluble fractions and analysed the
kinetics of Ab oligomerization. First, the soluble fraction
was subjected to photo-induced cross-linking followed by
SDS–PAGE and silver staining. This analysis revealed three
distinct time frames in which AChE-R affects Ab oligomer-
ization differentially (Fig. 2A). For the first 5 h of incu-
bation, Ab dimers, tetramers and pentamers were produced
with or without AChE-R. However, between the sixth and
seventh hours of incubation, most of the light Ab forms
(up to 20 kDa, corresponding to Ab pentamers) disap-
peared from the soluble samples including Ab alone, yet
were still clearly present when Ab was incubated with
AChE-R. After 20 h of incubation, no soluble oligomeric
forms of Ab were found regardless of the presence of
AChE-R (Fig. 2A). This reflected the generation of insoluble
fibrils, which became apparent from SDS–PAGE of the
insoluble Ab aggregates, resuspended in 8M urea. Thus,
after 6 and 7 h of incubation, the samples containing AChE-
R included considerably less insoluble Ab than those
without it (Fig. 2B). By 20 h of incubation, no differences
were found between the insoluble fractions with Ab alone
and with AChE-R, indicating that AChE-R delayed but did
not completely inhibit the formation of heavy Ab
oligomers. Interestingly, after 20 h of incubation, intact
AChE-R largely shifted from the soluble fraction (Fig. 2A)
into the insoluble fraction (Fig. 2B), indicating its direct
contact with the amyloid fibrils.
In addition to the full-length recombinant AChE-R, two
shorter peptides are also detectable by silver staining.
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Immuno-blot analysis using an antibody directed to the
unique C-terminus of AChE-R confirmed the identity of
these bands as an extended C-terminal AChE-R fragments
(Fig. 2A). Importantly, unlike intact AChE-R, these
peptides did not shift from the soluble fraction into the
insoluble fraction, suggesting that interaction with the
fibrils requires intact AChE-R. Together, these analyses
suggested that AChE-R production might serve to attenuate
amyloid fibrils formation and called for challenging this
prediction in an in vivo context.
AChE-R reduces plaque burden in
double transgenic APPsw/AChE-R mice
To test the ability of AChE-R to attenuate amyloid fibrils
assembly in vivo, we generated double-transgenic APPsw/
AChE-R mice by mating APPsw mice (Hsiao et al., 1996)
with AChE-R overexpressing ones (Pick et al., 2006) and
comparing their cortical plaque burden with that of single
transgenic APPsw mice. First, we wished to verify that
AChE-R levels are selectively higher in APPsw/AChE-R
mice as compared with the APPsw single transgenics.
Therefore, we fractionated hippocampal homogenates to
a LS fraction, enriched with soluble AChE-R and a LSD
fraction, enriched with membrane-anchored AChE-S.
Predictably, AChE-R but not AChE-S activity was higher
in APPsw/AChE-R mice (Fig. 3A and B). Nevertheless,
APPsw and APPsw/AChE-R mice showed similar summed
total AChE activity (364 57 and 318 105 nmol/min mg,
respectively), suggesting that the overall cholinergic balance
is maintained in these animals. Immuno-blot analysis
further validated that AChE-R overexpression did not
change APP levels in hippocampal homogenates (Fig. 3C).
Compatible with our in vitro results, APPsw/AChE-R mice
showed considerably lower cortical Ab plaque burden than
parent strain APPsw mice, as demonstrated by labelling
with the 6E10 anti Ab antibody, Congo red and thioflavin-S
stainings (Fig. 3D and E, P50.05, Mann–Whitney test in
Fig. 1 AChE-R attenuates while AChE-S facilitates Ab fibrils formation in vitro. (A) Scheme: AChE-S and AChE-R are produced from
alternatively spliced transcripts of the single ACHE gene. Exons 2, 3 and 4 (light grey) encode the common core of these variants. AChE-R
mRNA includes pseudo-intron 4 (40) and exon 5, whereas AChE-S mRNA includes exon 6.Their protein products deviate in their
C-terminal domains. Kinetics of Ab fibrils formation was monitored using thioflavinT (ThT) fluorescence over time. (B) Shown is dose
dependent effect of recombinant AChE-S protein on Ab1-40 fibrils formation. (C) Dose-dependent effect of recombinant AChE-R protein
on Ab1-40 fibrils formation. (D) Dose-dependent effect of recombinant AChE-S protein on Ab1-42 fibrils formation. (E) Dose-dependent
effect of recombinant AChE-R protein on Ab1-42 fibrils formation. (F) Simultaneous presence of both AChE-S and AChE-R at different
molar ratios. Note a dominant effect of AChE-R over AChE-S, resulting in inhibition of Ab1^40 fibrils formation. (G) Pre-incubation of
AChE-R with a specific antibody directed to the C-terminal domain (anti-R) results in loss of inhibitory effect.
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all labelling paradigms). Moreover, immuno-blotting of
SDS-insoluble pellets demonstrated lower levels of insoluble
Ab in hippocampal homogenates of APPsw/AChE-R mice
(Fig. 3F). This phenotype was a mirror image of that we
previously observed in APPsw/AChE-S mice (Rees et al.,
2005), substantiating our working hypothesis that these two
AChE isoforms, which only differ in their C-terminal
peptides (Meshorer and Soreq, 2006), exert inverse in vivo
effects on Ab fibrils formation both in vitro and in the
mouse brain.
AChE-R exerts in vivo and ex vivo
neuroprotection from Ab toxicity
We next examined whether the reduction in Ab plaque
burden in APPsw/AChE-R mice reflected decreased neuro-
toxicity. The density of reactive astrocytes surrounding Ab
plaques, an indicator of the inflammatory reaction
(Matsuoka et al., 2001), was quantified by assessing GFAP
labelling. Fewer reactive astrocytes appeared in the vicinity
of Ab plaques in the frontal cortex of double-transgenic
APPsw/AChE-R mice compared to their single-transgenic
littermates (Fig. 4A and B, P50.05). Since Ab plaques were
shown to associate with dendritic abnormalities (Tsai et al.,
2004), we further immunolabelled the microtubule-
associated protein MAP2 as a marker of dendritic integrity.
Single-transgenic APPsw mice showed reduced immuno-
reactivity of frontal cortex MAP2, an effect which was
Fig. 2 Kinetics of AChE-R’s effect on Ab oligomerizarion. Silver
staining of soluble (A) and insoluble (B) Ab samples incubated for
the indicated times with or without AChE-R. Note the difference
in soluble oligomeric and insoluble forms after 6 and 7h of incuba-
tion. Right insets: Silver staining (S.S) of recombinant AChE-R
reveals two bands, one of which with similar MW to Ab tetramers.
A similar size band is also detectable by immuno-blot (I.B) with an
anti-AChE-R antibody. Note a different scale for S.S and I.B.
Scheme: the experimental outline.
Fig. 3 AChE-R ameliorates Ab burden in double-transgenic APPsw/AChE-R mice. (A, B) Hydrolytic AChE activities in APPsw/AChE-R
hippocampi. Hippocampal AChE activities in transgenic brains were measured in low salt fraction, enriched with soluble AChE-R (A) and
low-salt detergent fraction, enriched with membrane-anchored AChE-S (B). AChE-R activity is 3-fold higher in APPsw/AChE-R mice
compared with APPsw transgenics (P50.01, Mann^Whitney test). (C) APP levels are not changed in APPsw/AChE-R. Immuno-blot
analysis of APPsw/AChE-R and APPsw hippocampal samples using the 6E10 antibody. (D, E) Ab plaque burden was assessed by labelling
sections from single transgenic APPsw and double-transgenic APPsw/AChE-R mice with the 6E10 antibody, congo red and thioflavin-S.
(D) Low magnification 6E10 immunoreactivity images of APPsw and APPsw/AChE-R mice. Scale bar=1mm (E) Representative enlarged
fields from the frontal cortex.Quantification graphs show area covered with plaques (% SEM). APPsw n=5, APPsw/AChE-R n=5.
Scale bar=200mm. (P50.05, Mann^Whitney test). (F) Insoluble Ab levels are reduced in APPsw/AChE-R mice. Immuno-blot analysis
of SDS-insoluble hippocampal samples with an 8M urea SDS^PAGE.
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ameliorated in double-transgenic APPsw/AChE-R mice
(Fig. 4C and D, P50.05). Importantly, GFAP labelling
was significantly and positively correlated with plaque
burden, whereas MAP2 labelling was inversely correlated
with this hallmark (Fig. 4B and D, P50.05). This bimodal
association validated the use of GFAP and MAP2 as
biomarkers, suggesting that AChE-R overexpression actively
delayed the Ab-induced damages in the frontal cortex for
over 75 weeks of age.
To yet more directly challenge the hypothesis that AChE-
R suppresses Ab neurotoxicity, synthetic Ab1-40 was
pre-incubated with or without recombinant human
AChE-R, at a 1:100 ratio (AChE-R:Ab), and mixtures
were applied to cultures of SH-SY5Y neuroblastoma cells.
Ab, but not AChE-R increased lactate dehydrogenase
(LDH) exclusion and decreased surviving cell counts
(Fig. 4E and F). Importantly, when added to Ab, AChE-R
attenuated its toxic effects, sustaining control LDH exclu-
sion values and cell survival as compared with Ab effects
(Fig. 4E and F).
Alzheimer’s disease patient hippocampi
show increased AChE-R mRNA but
reduced AChE-R protein levels
The finding that AChE-R promotes neuroprotection against
Ab-induced damages called for testing if the mRNA
expression and/or levels of this protein change in the
Alzheimer’s disease brain. We therefore examined the
expression levels of AChE variants in human hippocampal
tissues from Alzheimer’s disease patients and NDCs. First,
we explored AChE expression at the mRNA level using real-
time RT–PCR and FISH on hippocampal homogenates and
paraffin sections. RT–PCR analysis showed that AChE-R
mRNA constitutes 7% of AChE-S mRNA levels in the
hippocampus of NDCs (51921 14312 and 3781 686
copies/ng total RNA, respectively), close to the 1:20 ratio
we previously observed in newborn brain by cDNA
screening (Ben Aziz-Aloya et al., 1993). Importantly, we
found an 3-fold decrease in the level of the AChE-S
mRNA variant (P50.05) which was accompanied by
unchanged AChE-R mRNA levels in AD as compared
with NDC hippocampi (Fig. 5A and B). Because RNA
extracted from these tissue samples reflects a variety of
hippocampal cell types, we further used variant-specific
cRNA probes to label AChE variant mRNAs in hippocam-
pal neurons. Given that different probes have unique
hybridization characteristics, labelling intensity could only
be compared between samples labelled with a specific
probe. Extending the RT–PCR results, dentate gyrus (DG)
neurons of Alzheimer’s disease patients revealed signifi-
cantly reduced AChE-S mRNA levels (Fig. 5C and D,
P50.05). However, unlike the RT–PCR tests, the FISH
analysis detected a significant increase in AChE-R mRNA
within DG neurons of Alzheimer’s disease patients (Fig. 5C
and D, P50.05) as compared with its levels in NDCs.
Similar effects were also observed in CA1 neurons (data not
shown). Thus, AD hippocampal neurons produce less
AChE-S mRNA but more AChE-R mRNA as compared
with matched controls.
Fig. 4 AChE-R reduces Ab toxicity in vivo and ex vivo. (A) GFAP astrocytic labelling (red) around b-amyloid plaques (green) in frontal
cortices of APPsw and APPsw/AChE-R mice. Scale bar=50mm. (B) GFAP staining (percentage area covered SEM) and correlation to
Ab plaque burden. APPsw n=5, APPsw/AChE-R n=5. (P50.05, Mann^Whitney test, P50.05, Pearson test for correlation). (C) MAP2
labelling in APPsw and APPsw/AChE-R frontal cortices. Scale bar=50mm. (D) MAP2 staining (percentage area covered SEM) and cor-
relation to Ab plaque burden. APPsw n=5, APPsw/AChE-R n=5. (P50.05, Mann^Whitney test. P50.05, Pearson test for correlation).
(E) LDH exclusion test of human neuroblastoma SH-SY5Ycells incubated with 10mM Ab 1-40 alone or with 1:100 recombinant AChE-R
for 3 days. Note that AChE-R restores medium LDH activity to that of the control, while having no effect on its own. n=8,One of two
reproducible experiments. Error bars SD. (F) SH-SY5Ycell counts after treatment with 10mM Ab 1-40 alone or with 1:100 recombinant
AChE-R for 3 days. Note that AChE-R restores full cell survival in the presence of Ab 1-40. n=8, One of two reproducible experiments.
Error bars SD.
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Second, we measured AChE activity in hippocampal
homogenates to determine the total hydrolytic activities of
all AChE variants. An 30% reduction was predictably
found in AChE activity in our Alzheimer’s disease samples
compared to NDCs (Fig. 6A). Extraction of AChE-S
enriched, LS detergent hippocampal fraction, confirmed
that this reduction mainly results from reduced AChE-S
levels. Thus, the activity of AChE-S was compatibly reduced
by 20% in Alzheimer’s disease samples. Immuno-blot
analysis of hippocampal homogenates using polyclonal
antibodies that capture all AChE variants (Fig. 6, scheme)
further confirmed parallel reduction protein level, while
demonstrating several faster migrating bands reflecting
apparent proteolysis of hippocampal AChE (Fig. 6B).
Importantly, an antibody selective for the AChE-R variant,
revealed a drastic reduction of intact AChE-R levels, to
about 20% of NDC levels (Fig. 6C, P50.01). Additionally,
the anti-AChE-R antibody selectively detected substantially
shortened AChE-R fragments in the hippocampus of
Alzheimer’s disease patients. Several of these fragments
migrated similarly to those observed with the common
antibody, suggesting that AChE-R in the Alzheimer’s
disease hippocampus is particularly susceptible to the
disease-associated activation of proteases in the
Alzheimer’s disease brain (Saito et al., 1993; Su et al.,
2001).Together, these results demonstrated increased neu-
ronal AChE-R mRNA levels, which could potentially lead to
overproduction of this neuroprotective protein by alter-
native splicing shift from the AChE-S form to AChE-R.
However, protein analysis showed almost completely
diminished AChE-R protein in the Alzheimer’s disease
brain, suggesting apparent malprotection.
Discussion
Alternative splicing serves to increase the repertoire of
protein products from single genes (Maniatis and Tasic,
2002). Often, splice variants of specific genes play inverse
roles in cell fate and function (Shin and Manley, 2004). Our
current study demonstrates that this is the case also for
Fig. 5 Splice shift from AChE-S mRNA to AChE-R mRNA in
hippocampal tissue of Alzheimer’s disease patients. (A) Location
of primers (arrows) and in situ hybridization probes (asterisks)
used. (B) Real-time RT^PCR absolute quantification AChE splice
variants from human hippocampal RNA. AChE-S mRNA levels
are significantly reduced in Alzheimer’s disease (n=10) compared
to non-demented control patients (NDC, n=5). Copy number?
103/ng RNA SEM. (P50.05, Mann^Whitney test). (C)
Fluorescent in situ hybridization (FISH) of human hippocampal
sections using cRNA probes specific for each variant. Shown is
the dentate gyrus (DG) area. Scale bar=50 and 10mm in
micrographs and insets, respectively. (D) Fluorescent signal
quantification shows decreased AChE-S and increased AChE-R
mRNA levels in Alzheimer’s disease DG compared to NDC
neurons. Fold change from NDC SEM. (P50.05, Mann^
Whitney test).
Fig. 6 AChE-R protein levels are reduced in the hippocampus of
Alzheimer’s disease patients. (A) Total AChE activity was mea-
sured in hippocampal homogenates from10 Alzheimer’s disease
patients and five non-demented controls (NDC). (B) Total AChE
immuno-blot of hippocampal homogenates from NDCs and
Alzheimer’s disease patients. A 30% decrease in labelling intensity
of intact AChE is observed, similar to that seen in AChE activity.
Note the presence of shorter degradation products (filled circle).
Scheme: Total AChE was immuno-detected by an antibody that
captures all AChE variants (H134). (C) A specific antibody against
AChE-R (anti-R) detected reduction to 20% of NDC levels in
AChE-R protein levels from hippocampal homogenates of
Alzheimer’s disease patients (P50.01, Mann^Whitney test).
R marks recombinant AChE-R positive control. -tubulin labelling
is shown as loading control in both (B) and (C). Note the
Alzheimer’s disease-associated increase in AChE-R degredation
products (filled circle) migrating similarly to those labelled with
the H134 antibody.
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AChE splice variants, in the context of their inverse roles
in Alzheimer’s disease neuropathology. Compatible with
previous findings, we found facilitated amyloid fibrils
formation by AChE-S (Inestrosa et al., 1996; Rees et al.,
2005). However, unlike AChE-S, we observed physiologi-
cally relevant and dose-dependent inhibition of Ab fibrils
formation by AChE-R in vitro, ex vivo and in vivo,
in double-transgenic APPsw/AChE-R mice. Moreover,
AChE-R limited the cellular toxicity of Ab, reduced cortical
astrocytes activation and protected dendritic integrity, all
inverse to the capacity of AChE-S to increase the
neurotoxic effect of Ab (Alvarez et al., 1998). Finally, we
observed hippocampal loss of AChE-R in Alzheimer’s
disease patients, suggesting physiological relevance for Ab
neuropathology in the Alzheimer’s disease brain. The two
splice variants of AChE therefore exert multileveled inverse
effects on both Ab fibrils formation and neurotoxicity.
Of note, the observed increase of AChE-R mRNA by in situ
hybridization of hippocampal neurons and not by RT–PCR
of the entire tissue suggests that this increase may only take
place within neurons.
In mammals, AChE-R overexpression is induced by
multiple stress stimuli as well as by aging (Meshorer and
Soreq, 2006). Accordingly, we found an increase in the
neuronal levels of AChE-R mRNA in Alzheimer’s disease
hippocampi, compatible with the stress and anxiety
involved in Alzheimer’s disease progression (Masugi et al.,
1989; Green et al., 2006). In addition, neuronal increase
of AChE-R mRNA may also result from a feedback
mechanism following the degradation of the AChE-R
protein and/or other Alzheimer’s disease-related processes.
However, to fully exert its protective effects, AChE-R
mRNA must yield the intact AChE-R protein. This does not
occur in the Alzheimer’s disease brain: unlike normal aging,
the AChE-R protein is substantially downregulated in
Alzheimer’s disease, suggesting that an Alzheimer’s dis-
ease-related process is responsible. It is note worthy that
both AChE-R mRNA and the AChE-R protein are less
stable than the corresponding AChE-S mRNA and AChE-S
protein (Chan et al., 1998; Cohen et al., 2003). Therefore,
alternative 30 splicing of the AChE pre-mRNA transcript
likely operates to increase the levels of the neuroprotective
AChE-R but the protein product does not accumulate,
likely due to exacerbated proteolysis. Interestingly, AChE
fragments corresponding in size to those found in
Alzheimer’s disease hippocampal homogenates were also
detected, albeit faintly, in NDCs by both anti-AChE and
anti-AChE-R antibodies. However, a drastic increase in the
immunoreactivity of these fragments was only detected by
the anti-AChE-R antibody. Therefore, it appears that
selective proteolysis of the AChE-R protein, which accounts
for roughly 10% of total AChE, is induced in the
Alzheimer’s disease hippocampus. Moreover, it has been
previously shown in a 1-year follow-up study (Darreh-Shori
et al., 2004) that untreated Alzheimer’s disease patients
exhibit a selective decline in AChE-R levels over time.
Therefore, preliminary evidence suggests that the decline
in AChE-R levels correlates with the disease progression.
In the same study, rivastigmine administered for 1 year
induced CSF AChE-R expression and a higher AChE-R/
AChE-S ratio correlated with sustained cognition and
improved behaviour in these Alzheimer’s disease patients.
Together, this supports the role of AChE-R as a neuro-
protective agent. Interestingly, tacrine treatment resulted in
a general upregulation of AChE, suggesting that AChE
inhibitors exert different effects on the expression of
specific AChE variants and that inhibitors which selectively
increase AChE-R levels may be more potent drugs
operating in a dual mode of action.
Amyloid fibrils formation involves generation of different
intermediates with distinct toxic effects, which precede the
formation of mature fibrils and aggregates (Ross and
Poirier, 2004; Lesne et al., 2006). Our cross-linking findings
suggest that AChE-R interferes with the earliest stages of Ab
formation, providing the grounds for mechanistic explana-
tion of the AChE-R-dependent reduction in Ab toxicity.
In these experiments, the AChE-R attenuation effect was
limited in its duration. However, enforced increase of
AChE-R by 3-fold sufficed to reduce plaque burden in
75-week-old mice. This difference between the in vitro and
in vivo outcome of AChE-R excess may be due to the
distinct experimental conditions: In vitro, we used highly
purified AChE-R and synthetic Ab; in vivo, many other
proteins could have affected fibrils formation.
AChE-S and AChE-R have identical enzymatic character-
istics including Km (0.33 0.092, 0.29 0.035 for AChE-R
and AChE-S, respectively) and substrate inhibition (Farchi
et al., 2007). It is therefore expected that the different
effects of AChE-S and AChE-R arise from non-enzymatic
properties such as protein–protein interactions of their
unique C-termini and/or their differential location in the
synapse in vivo (membrane anchored and soluble,
respectively).
Structural studies suggest that both AChE-S and AChE-R
include the peripheral anionic site (PAS) reported to
promote Ab fibril formation (Alvarez et al., 1998).
However, they differ in their C-termini, suggesting that
this region is responsible for the variant-specific effects on
fibrils formation. For comparison, the AChE-homologous
enzyme BChE, exerts a similarly effective attenuation of Ab
fibrils formation via its C-terminal domain, in a process
involving an impaired amphipathicity due to a protruding
aromatic tryptophan residue (Diamant et al., 2006). AChE-
R’s C-terminus includes two tryptophan residues that may
be functionally involved in Ab fibril interactions (Wang and
Hecht, 2002; Gazit, 2005). However, the C-terminal peptide
of BChE likely resumes a helical structure, whereas the
C-terminal peptide of AChE-R is a naturally unfolded
peptide (Circular dichroism spectroscopy, data not shown).
Further research will be required to determine the structure
resumed by this naturally unfolded peptide when interact-
ing with Ab.
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That overexpression of AChE-R protects neurons from
both aging (Sternfeld et al., 2000) and Ab-induced
neuropathologies, and that it elevates hippocampal long-
term potentiation (Nijholt et al., 2004) supports the notion
that the selective loss of AChE-R has a pivotal role in
the Ab-induced toxicity in AD. Thus the ability of AChE-R
to protect against aging-dependent neurodeterioration also
in mice lacking amyloid pathology further suggests that
AChE-R can protect neurons by additional mechanism(s)
apart from delaying Ab fibrils formation. Compatible
with this hypothesis, AChE-R excess also protects dopami-
nergic neurons from MPTP neurotoxicity (Ben-Shaul et al.,
2006). Therefore, AChE-R loss may contribute by itself
to neuronal toxicity in Alzheimer’s disease. Failure to
overproduce AChE-R at need is also likely to impair
cognitive stress reactions (Meshorer and Soreq, 2006).
Supporting this suggestion, transgenic downregulation
of AChE-R results in failure to terminate neuronal stress
reactions accompanied by impaired dendritic formation
(Sklan et al., 2006).
Taken together, our findings reveal a novel linkage
between the cholinergic system and amyloid pathology
while changing the common understanding of AChE’s
involvement in Alzheimer’s disease. The inverse in vitro,
ex vivo and in vivo effects of the AChE-S and AChE-R splice
variants on amyloid fibril formation, further suggest
alternative splicing-induced differences as the underlying
mechanism for these distinct effects. Our findings of a
neuroprotective effect of AChE-R may further foreshadow a
putative future therapeutic treatment involving the AChE-R
protein.
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